Literature DB >> 17563214

Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics.

Damaris J Rohsenow1, Robert Miranda, John E McGeary, Peter M Monti.   

Abstract

Naltrexone's (NAL) effects on alcohol consumption are generally modest, so identifying patients likely to benefit would improve treatment utility. Several studies indicate that potentially significant moderators of NAL's effects might include family history of alcohol problems (FH), age of onset of alcohol problems, degree of antisocial traits, and comorbid drug use. Data from 128 alcoholic patients enrolled in a 12-week NAL treatment study (50 mg/day) were reanalyzed to determine the role of FH, age of onset, antisocial traits, and comorbid drug use in NAL's treatment effects on heavy drinking days. Dichotomized FH, age of onset of alcohol problems, and comorbid cocaine or marijuana use had no interaction effect with medication. Percentage of relatives with problem drinking (family history percentage [FHP]) moderated the effects of NAL on drinking such that NAL resulted in lower drinking rates only for patients with higher FHP. Antisocial traits also moderated the effects of medication on drinking for patients compliant with =70% of medication. Patients with more antisocial traits had less heavy drinking on NAL than on placebo, whereas patients low on antisocial traits had no benefit from NAL. Covarying antisociality in regressions of drinking outcome on FHP showed that the effects of FHP were not attributable to antisociality. Thus, NAL may selectively benefit alcoholics with antisocial traits or 20% or more relatives with problem drinking. (c) 2007 APA, all rights reserved

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17563214     DOI: 10.1037/1064-1297.15.3.272

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  16 in total

Review 1.  Targeted opioid receptor antagonists in the treatment of alcohol use disorders.

Authors:  Mark J Niciu; Albert J Arias
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

2.  Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial.

Authors:  George A Kenna; Carolina L Haass-Koffler; William H Zywiak; Steven M Edwards; Michael B Brickley; Robert M Swift; Lorenzo Leggio
Journal:  Addict Biol       Date:  2015-06-02       Impact factor: 4.280

3.  Mu-opioid antagonism in the treatment of cannabis use disorder

Authors:  Oussama Kebir; Xavier Laqueille; Fayçal Mouaffak
Journal:  J Psychiatry Neurosci       Date:  2020-03-01       Impact factor: 6.186

4.  Effectiveness of a Feedback-Based Brief Intervention to Reduce Alcohol Use in Community Substance Use Disorders.

Authors:  Blaise L Worden; Barbara S McCrady
Journal:  Alcohol Treat Q       Date:  2013

5.  Effects of alcoholism typology on response to naltrexone in the COMBINE study.

Authors:  Michael P Bogenschutz; J Scott Tonigan; Helen M Pettinati
Journal:  Alcohol Clin Exp Res       Date:  2008-09-30       Impact factor: 3.455

6.  Effects of naltrexone on cortisol levels in heavy drinkers.

Authors:  Lara A Ray; James Mackillop; Lorenzo Leggio; Marilee Morgan; Kent E Hutchison
Journal:  Pharmacol Biochem Behav       Date:  2008-09-13       Impact factor: 3.533

7.  Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence.

Authors:  James C Garbutt; Michael Osborne; Robert Gallop; John Barkenbus; Kathy Grace; Meghan Cody; Barbara Flannery; Alexey B Kampov-Polevoy
Journal:  Alcohol Alcohol       Date:  2009-02-03       Impact factor: 2.826

8.  Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.

Authors:  Jennifer W Tidey; Peter M Monti; Damaris J Rohsenow; Chad J Gwaltney; Robert Miranda; John E McGeary; James MacKillop; Robert M Swift; David B Abrams; Saul Shiffman; Jean A Paty
Journal:  Alcohol Clin Exp Res       Date:  2007-11-20       Impact factor: 3.455

9.  A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.

Authors:  Sung-Gon Kim; Cheol-Min Kim; Sam-Wook Choi; Young-Myo Jae; Hae-Gook Lee; Bong-Ki Son; Jeong-Gee Kim; Young-Sung Choi; Han-Oh Kim; Seong-Yeon Kim; David W Oslin
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

10.  A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention.

Authors:  David W Oslin; Kevin G Lynch; Helen M Pettinati; Kyle M Kampman; Peter Gariti; Lois Gelfand; Thomas Ten Have; Shoshana Wortman; William Dundon; Charles Dackis; Joseph R Volpicelli; Charles P O'Brien
Journal:  Alcohol Clin Exp Res       Date:  2008-07       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.